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Abstract
The recruitment of bone marrow (BM)-derived progenitor cells to the lung is related to pulmonary remodelling and the pathogenesis of
pulmonary hypertension (PH). Although sildenafil is a known target in PH treatment, the underlying molecular mechanism is still elusive.
To test the hypothesis that the therapeutic effect of sildenafil is linked to the reduced recruitment of BM-derived progenitor cells, we
induced pulmonary remodelling in rats by two-week exposure to chronic hypoxia (CH, 10% oxygen), a trigger of BM-derived progenitor
cells. Rats were treated with either placebo (saline) or sildenafil (1.4 mg/kg/day ip) during CH. Control rats were kept in room air (21%
oxygen) with no treatment. As expected, sildenafil attenuated the CH-induced increase in right ventricular systolic pressure and right ven-
tricular hypertrophy. However, sildenafil suppressed the CH-induced increase in c-kit+ cells in the adventitia of pulmonary arteries. More-
over, sildenafil reduced the number of c-kit+ cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and CD68 (a marker for
macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without
affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a. Furthermore, sildenafil depressed the number of CXCR4+ cells. Collec-
tively, these findings indicate that the improvement in pulmonary haemodynamic by sildenafil is linked to decreased recruitment of BM-
derived c-kit+ cells in the pulmonary tissue. The attenuation of the recruitment of BM-derived c-kit+ cells by sildenafil may provide novel
therapeutic insights into the control of pulmonary remodelling.
Keywords: chronic hypoxia sildenafil bone marrow progenitor cells pulmonary hypertension c-kit cells CXCR4
receptor
Introduction
Pulmonary hypertension (PH), a progressive disease of the pul-
monary arterioles characterized by vascular remodelling that results
in increased pulmonary arterial pressure [1], might lead to fatal right
ventricular (RV) heart failure. Despite recent substantial progress in
treatment, the prognosis remains poor [2], urging the need to identify
new therapeutic targets. Chronic hypoxia (CH) contributes to PH [3]
and is associated with many PH-related diseases, including chronic
obstructive pulmonary disease, cystic fibrosis, diffuse interstitial
fibrosis, bronchopulmonary dysplasia, infiltrative lung tumours, con-
genital hearts defects and ischaemic events.
Previous reports show that the process of vascular remod-
elling induced by hypoxia involves the mobilization of bone mar-
row (BM)-derived progenitor cells expressing the transmembrane
tyrosine kinase receptor c-kit [4, 5]. BM-derived c-kit+ cells
mobilization into the peripheral circulation creates an environment
in the pulmonary artery vessel wall that facilitates adhesion of
circulating cells. Many studies identified BM-derived progenitors
as important players in vascular pathology [4–6]. Thus strategies
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that inhibit the recruitment of these cells to pulmonary arteries
may constitute important therapeutic options for PH, and the tyr-
osine kinase inhibitors imatinib and sorafenib were found to alle-
viate PH in experimental models [6, 7]. Although imatinib
showed favourable effects in human beings [8], this drug has
multiple targets with difficult prediction of the risk-benefit ratio
and may induce cardiotoxicity [9, 10], thus urging the need to
explore alternative strategies. The effect of sildenafil, a non-toxic
phosphodiesterase-5 (PDE-5) inhibitor, on the loss of endothe-
lium-derived nitric oxide (NO) has provided a background for its
use in the clinical treatment of PH [11, 12]. By inhibiting cyclic
guanosin mononucleotide (cGMP) breakdown to inactive 50-gua-
nosin mononucleotide (50-GMP), sildenafil increases the phospho-
rylation and activation of the endothelial isoform of NOS (eNOS)
and of protein kinase B (Akt), thereby reducing apoptosis [13,
14] and contrasting PH-induced pathology. However, the underly-
ing mechanism is not yet clear.
Rat breathing 10% O2 for 15 days develop RV hypertrophy that is
partially corrected by sildenafil [15, 16]. Furthermore, CH is a power-
ful activator of stromal cell-derived factor-1a (SDF-1a) cell receptor,
CXC chemokine receptor 4 (CXCR4) [6, 17, 18]. This axis plays an
important role in the migration of BM stem cells to lung lesions, as
supported by data showing that its inhibition prevents c-kit+ cell accu-
mulation in pulmonary arteries and thus PH development [6, 17].
Therefore, the aim of the present investigation was to test whether
the mechanism underlying the attenuation of CH-induced pulmonary
remodelling by PDE-5 inhibition might involve BM-derived progenitor
cells.
Materials and Methods
Animals and study design
Experiments were conducted on a total of 49 male eight-week-old
Sprague Dawley rats (Charles River, France). Rats were fed stan-
dard diet without limitations until 24 hrs before killing. Room tem-
perature was kept at 21  2°C and 12 hrs of light was alternated
with 12 hrs of dark. Experiments were performed in accordance
with the Swiss federal law, the Guide for the Care and Use of Lab-
oratory Animals published by the US National Institutes of Health
(NIH Publication No. 85-23, revised 1996) and the guidelines indi-
cated in the Declaration of Helsinki of 1972. The protocol was
approved by the Committee of the Ethics of Animal Experiments,
Office Veterinaire Cantonal, Lausanne. All efforts were made to mini-
mize animal suffering.
Rats were subdivided into three groups: control (breathing atmo-
spheric air at 21% O2; n = 10), CH rats (breathing air at 10% O2)
treated with placebo (saline; n = 12) and CH rats treated with silde-
nafil (1.4 mg/kg/day, i.p., n = 12). All treatments had a fixed dura-
tion of 15 days. At the end of treatments, rats were anaerobically
transferred into the compensation chamber flowed with either 21%
or 10% O2, as described previously [15, 16, 19, 20] and anes-
thetized by i.p. injection of ketamine (100 mg/kg) plus xylazine
(10 mg/kg).
Haemodynamic measurements
The anesthetized rats were placed over a heating platform at 37°C and
connected to a mechanical ventilator after tracheotomy (tidal volume
2.5 ml at 50 strokes/min.) using a Harvard Apparatus (model 683; Hollis-
ton, MA, USA) with either room air or hypoxic gas for control and hypoxic
groups, respectively. To evaluate right ventricular (RV) pressure, the tho-
rax was opened and a 25-G needle was inserted into the RV apex,
enabling the placement of a Millar Mikro-Tip conductance catheter (model
SPR-838, tip size of 2F; Millar Instruments, Oxford, UK) along the long
axis of the heart. After stabilization, the RV systolic pressure was recorded
for each animal using an MPVS Ultra system (Millar Instruments). To
evaluate the left ventricular (LV) pressure, the right carotid artery was
cannulated with the Millar catheter, advanced into the LV cavity in the
closed-chest preparation and the LV systolic pressure was measured as
described above.
Blood gas analysis
Arterial blood was withdrawn from the left carotid artery of thoraco-
tomized rats in a heparinized syringe and blood gasses were immedi-
ately measured (Servomex Oxygen Analyzer 570 A; Zurich, Switzerland).
The base excess (BE) was calculated from arterial pH and PCO2 using
the formula [21]: BE = 0.02786 9 PCO2 9 10
(pH - 6.1) + 13.77 9 pH -
124.58. The remaining blood was centrifuged and plasma stored at -
80°C for analysis of cGMP (ELISA kit; Assay designs, Inc., Ann Arbor,
MI, USA).
Lung morphology
At the end of the haemodynamic study, rats were killed with an
overdose of anaesthesia, the lungs were inflated with 10% formalin
at 25 cm H2O pressure through the trachea for 15 min., excised and
finally processed for paraffin embedding. Lung sections (8 lm thick)
were stained with an antibody against a-smooth muscle actin (a-
SMA 1:250, clone 1A4; Sigma-Aldrich, Buchs, Switzerland) overnight
at 4°C, followed by a goat antimouse IgG secondary antibody (1:500,
Dako, DK-2600 Glostrup, Denmark), and all transversally cut arteri-
oles were quantitatively analysed at 2009 magnification using an
images analysis system Nikon eclipse 80i camera and NIH image
software (NIKON INSTRUMENTS INC. Melville, NY, USA).
Pulmonary arterial thickening was assessed by calculating the per
cent pulmonary artery thickness using the following formula:
100 9 (perivascular area-luminal area)/luminal area. For this mea-
surement, 20 arteries/sample of <50 lm were analysed. The degree
of muscularization of small pulmonary arterioles was assessed from
immunofluorescence staining with primary antibodies rabbit polyclonal
a-SMA (1:100, Abcam 5694) and mouse monoclonal PECAM-1
(D-11, 1:100; Santa Cruz, Dallas, TX, USA) and the secondary anti-
bodies rabbit Alexa Fluor-594 (1:500) or mouse Alexa Flour-488
(1:500). Sections were examined using a confocal microscope. The
percentage of muscularization of vessels from a-SMA and PECAM-1
florescence was analysed for threshold intensity and expressed as
a percentage of total vessel area using imageJ software (NIH). All
the morphological analysis was conducted in a double-blind method.
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Immunofluorescence and immunohistochemical
staining
The procedure for immunofluorescence staining is described elsewhere
[22]. The following antibodies (Santa Cruz) were used: c-kit (H-300 rabbit
polyclonal, 1:100), VEGF-R2 (A-3, mouse monoclonal, 1:50) and CD68
(H-255, rabbit polyclonal, 1:80). To detect colocalization with VEGF-R2 or
CD68, slides were double-stained with mouse monoclonal VEGF-R2 and
mouse monoclonal CD68 and goat secondary antibody rhodamine-conju-
gated (Santa Cruz), diluted 1:200 in PBS. Five distinct images per section
were acquired by a Zeiss LSM 710 confocal microscope. Results are
expressed as number of c-kit+/VEGF-R2+ or c-kit+/CD68+ cells/vessel.
For CXCR4 and Ki-67 immunofluorescence staining, antigen retrieval
was performed by heat in citrate buffer (pH 6.0) for 20 min. Then, sec-
tions were washed and blocked for 1 hr at room temperature with 10%
goat serum to saturate any non-specific bindings, followed by overnight
incubation at 4°C with the primary antibody CXCR4 (1:100, Santa Cruz)
or Ki-67 (ab66155). After washing, the sections were incubated with
secondary antibody, Alexa 647-conjugated goat anti-rabbit IgG (1:400,
Life Technologies Waltham, MA, USA) for 1 hr. All sections were coun-
terstained with Hoechst 33342 staining (1:1000) and mounted with fluo-
rescent mounting medium (Dako). Five sections per group were
acquired using a Zeiss LSM 710 confocal microscope. Cell proliferation
was quantified as number of Ki-67-positive cells/total nuclei and all
CXCR4+ cells in the perivascular pulmonary arterioles were counted.
Results are expressed as number of CXCR4+ cells/vessel. HIF-1a
immunohistochemical staining was performed as described [23].
Biochemical measurements
An additional set of experiments (n = 15 rats) was performed for bio-
chemical analysis. Lungs were quickly rinsed in ice-cold PBS (pH 7.4)
and clamped between steel tongs pre-cooled with liquid N2 and stored
at -80°C until analysis. For Western blotting analyses, frozen lung tis-
sues were homogenized in lysis buffer plus protease inhibitor cocktail
(Santa Cruz Biotechnology) and processed as described elsewhere [24],
using the following primary antibodies: anti-p-eNOS (Ser1177, Cell Sig-
nalling Technology), anti-eNOS (Santa Cruz Biotechnology), anti-p-Akt
(Ser473) and anti-Akt (both Cell Signaling Technologies). Band intensities
were quantified using ImageJ software.
Real-time PCR analysis
Total RNAs of lung tissues were extracted using TRIzol reagent and
reversed-transcribed with oligo-dT primers [Thermo Scientific (Waltham,
MA, USA), Verso cDNA Synthesis Kit]. Quantitative RT-PCR was per-
formed with the use of QuantiStudio 6 Applied Biosystem real-time
detection system (Life technologies, Waltham, MA, USA) and the Fast
SYBR Green Master Mix (Applied Biosystem, Waltham, MA, USA) fol-
lowing the manufacturer’s instructions. PCR program was as follows:
94°C for 30 sec., 40 cycles of 95°C for 5 sec., 56°C for 30 sec., 72°C
for 20 sec. The relative amount of mRNA expression for hypoxia-induci-
ble factor-1a (HIF-1a) was represented using the 2-ΔΔCt value. The pri-
mer pairs for HIF-1a PCR (138 bp) were (forward) 50-
TGAGCTCACATCTTGATAAAGCTTCT-30 and (reverse) 50-GGGCTTTCAGA-
TAAAAACAGTCCAT-30, and for the housekeeping gene GAPDH (359 bp)
were (forward) 50-TGAAGGTCGGTGTGAACGGATTTG-30 and (reverse) 50-
GGCGGAGATGATGACCCTTTTG-30, respectively.
FACS analysis
Whole blood was mixed with 5 lM EDTA to prevent clotting, stained for
15 min. at room temperature with suitable combinations of the following
monoclonal antibodies or isotype-matched control monoclonal antibodies:
CXCR4 FITC (Alomone Labs, Jerusalem, Israel) and CD177(c-kit) PE (BD
Pharmingen, Italy). Red blood cells were lysed with the use of BD Pharm
Lyse (BD Biosciences, Milan) and analysed with the use of a Gallios Flow
Cytometer (Beckman Coulter, Inc., Brea, CA, USA) equipped with Kaluza
Software.
Statistical analysis
Data are expressed as mean  SEM. To detect differences among the
groups, we used the one-way ANOVA test followed, if significant, by the
Table 1 Arterial blood gas analysis and blood values (mean  SEM)
Control Chronic hypoxia + saline Chronic hypoxia + sildenafil ANOVA P
N 15 17 17
Weight gain, g 103  5 13  8* 3  5* <0.0001
PaO2, mmHg 83.5  7.8 40.3  2.8* 42.5  2.8* <0.0001
PaCO2, mmHg 39.3  2.0 26.1  2.5* 25.4  1.3* 0.0001
pH 7.43  0.01 7.40  0.02 7.42  0.02 NS
Base excess, mEq/l 0.7  0.8 8.3  0.8* 8.2  0.5* <0.0001
Haematocrit, % 41  2 66  1* 62  1*# <0.0001
cGMP, nM 2.18  0.32 2.34  0.27 4.64  0.91*# 0.01
*P < 0.05 versus control, #P < 0.05 versus chronic hypoxia + saline (Bonferroni multiple comparison test).
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Fig. 1 Sildenafil preserves survival pathways in hypoxia. (A) Left panel. Representative Western blots of whole pulmonary tissue homogenates for
phospho-eNOS (P-eNOS), eNOS, phospho-Akt (P-Akt) and Akt. GAPDH was used as a loading control. Right panel. Densitometric analysis, calcu-
lated as fold increase versus control. (B) Left panel. Representative confocal immunofluorescence images of pulmonary tissue stained with antibody
against Ki-67 (red) with nuclei counterstained with HOECHST (blue). Right panel. Percentage of cells with a positive nuclear staining for Ki-67 with
respect to all nuclei. Scale bars = 20 lm. Data are presented as meanSEM (n = 5/group); *P < 0.05 versus control, #P < 0.05 versus chronic
hypoxia (CH) (one-way ANOVA with Bonferroni post-test).
Fig. 2 Sildenafil reduces hypoxia-induced
increase in c-kit+ cell recruitment. (A)
Representative confocal immunofluores-
cence staining for c-kit+ cells (red). Nuclei
were counterstained with HOECHST (blue).
Scale bar = 20 lm. The plot (B) shows
the quantification of the number of c-kit+
cells/vessel (5 fields per section). Same
details as in Fig. 1.
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Bonferroni’s test to the differences between data pairs. Significance
level was set at P = 0.05 (two-tailed).
Results
Sildenafil restores cGMP levels and preserves
survival pathways in hypoxia
Chronic hypoxia induced striking changes in blood gasses and base
excess (Table 1), which were not affected by sildenafil. Plasma cGMP
levels were higher in CH-sildenafil rats compared with CH-placebo
and control rats, demonstrating that cGMP conversion to 50-GMP
was efficiently inhibited by sildenafil. The expression of eNOS and Akt
in pulmonary tissue did not change among groups (Fig. 1A), but
phospho-eNOS at Ser1177 and phospho-Akt at Ser473 were decreased
in CH compared with control and sildenafil was able to rescue such
decrease. Additionally, sildenafil significantly increased both phos-
pho-eNOS/eNOS and phospho-Akt/Akt ratios (Fig. 1A). As Akt is a
key mediator of cell proliferation, we evaluated the level of prolifera-
tion in pulmonary tissue. CH increased Ki-67-positive nuclei, whereas
sildenafil markedly reduced the degree of proliferation (Fig. 1B).
Sildenafil reduces hypoxia-induced increase in
c-kit+ cell recruitment
Emerging evidence suggests the importance of the BM-derived pro-
genitor cell population expressing the c-kit marker in the process of
vascular remodelling [25]. Because sildenafil is able to modulate
c-kit+ cell mobilization into peripheral blood under CH (Fig. S1), we
Fig. 3 Sildenafil reduced hypoxia-induced
increase in c-kit+/VEGF-R2+g. Representa-
tive confocal immunofluorescence costain-
ings for c-kit+ (red) and VEGF-R2 (green).
Nuclei were counterstained with HOECHST
(blue). Scale bars = 50 lm. The plot
shows the quantification of the number of
c-kit+/VEGF-R2+ cells (5 fields per sec-
tion). Same details as in Fig. 1.
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measured c-kit+ cells mobilization in lungs. Immunostaining of the
perivascular pulmonary artery showed that the number of c-kit+ cells
per vessel was higher in CH compared with control (Fig. 2). This
effect was markedly reduced by sildenafil.
Sildenafil modulates progenitor cell nature of
c-kit+ cells
Chronic hypoxia significantly increased the number of c-kit+/VEGF-R2+
(Fig. 3) and c-kit+/CD68+ cells (Fig. 4) compared with control and silde-
nafil reduced this number. This indicates important effects of CH and
sildenafil on muscularization and inflammation. To assess the first, we
measured the level of muscularized versus non-muscularized vessels
by a-SMA and PECAM-1 costaining as described in Materials and
Methods. Figure 5A shows that whereas CH increased muscularization,
sildenafil reversed remodelling. Consistently, in three representative
confocal immunofluorescence images targeted at identifying vascular
smooth muscle cells (VSMC), we found that sildenafil reduced VSMC
proliferation (Fig. 5B). To support the occurrence of inflammatory pro-
cesses, we measured by confocal microscopy the recruitment of CD68
cells and found that sildenafil could reduce such recruitment (Fig. 5C).
Sildenafil regulates mobilization and recruitment
of CXCR4+ cells
Chronic hypoxia increased mRNA expression of the hypoxia-inducible
factor (HIF)-1a (Fig. 6A left panel). However, sildenafil did not change
it, supporting the view that sildenafil did not act on the degree of
hypoxia (see also Table 1). Furthermore, immunohistochemical stain-
ing showed that HIF-1a expression was higher in CH than in control
pulmonary tissue (Fig. 6A, right panel) and was not affected by silde-
nafil. Because CH increased the plasma level of CXCR4+ cells and
Fig. 4 Sildenafil reduced hypoxia-induced
increase in c-kit+/CD68+. Representative
confocal immunofluorescence costainings
for c-kit+ (red) and CD-68 (green). Nuclei
were counterstained with HOECHST (blue).
Scale bars = 50 lm. The plot shows the
quantification of the number of c-kit+/
CD68 cells (5 fields per section). Same
details as in Fig. 1.
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sildenafil tended to blunt such increase (Fig. S2), we evaluated the
mobilization and recruitment of CXCR4+ cells in pulmonary tissue by
confocal immunostaining. Whereas CH increased the number of
CXCR4+ cells in the perivascular wall of small pulmonary arteries
(Fig. 6B), sildenafil attenuated the number of these cells, further sup-
porting the antimobilization role of sildenafil.
Outcome of altered recruitment of c-kit+ cells
To understand how the phenomena described above translate into
clinically relevant outcome, we explored angiogenesis and some
downstream physiological effects. We first calculated the number of
lung tissue vessels <50 lm diameter by a-SMA staining (Fig. 7A).
CH increased this value and sildenafil attenuated such increase. We
also assessed the degree of pulmonary vascular remodelling by
measuring the medial wall thickness of small pulmonary arteries
(Fig. 7B). Compared with control, CH group had a significant increase
in medial wall thickness, which was attenuated by sildenafil treatment.
To assess the cardiopulmonary effect of sildenafil during CH, we mea-
sured the right ventricle hypertrophy and the cardiac load in the LV
and RV (Fig. 7C and D, respectively). While CH induced an increase in
the RV/LV + S weight ratio, sildenafil nearly blunted this increase.
Furthermore, whereas LV pressures were only marginally affected,
RV pressures were increased in CH compared with control rats. Treat-
ment with sildenafil decreased RV systolic pressure, indicating that it
may attenuate the development of CH-induced PH.
Discussion
Data gathered in this study support the hypothesis that sildenafil, a
PDE-5 inhibitor, attenuates CH-induced pulmonary vascular remod-
elling and dysfunction by modulating BM-derived c-kit+ progenitor
cell recruitment into the lungs. This finding is particularly relevant in
the context of PH because it was recently reported that BM-derived
Fig. 5 Effects of chronic hypoxia (CH) and sildenafil on muscularization and inflammation. (A) Left panel. Representative confocal images of vessels
stained with a-SMA (red) and PECAM-1 (green). The plot (right panel) shows the index of muscularization of vessels calculated as per cent of a-
SMA staining on PECAM-1-positive vessels. Same details as in Fig. 1. (B) Representative confocal immunofluorescence staining of pulmonary sec-
tions for a-SMA (green) and Ki-67 (red). Nuclei were counterstained with HOECHST (blue). Scale bars = 20 lm. (C) Representative confocal
immunofluorescence staining of pulmonary sections for CD68 (red) and Ki-67 (green). Nuclei were counterstained with HOECHST (blue). Scale
bars = 20 lm.
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Fig. 6 Sildenafil regulates mobilization and recruitment of CXCR4+ cells. (A) Left panel. mRNA quantification of HIF-1a. Same details as in Fig. 1.
Right panel. Immunohistochemical staining (brown) of HIF-1a in haematoxylin pulmonary sections. (B) Left panel. Representative confocal micro-
scopy images for CXCR4 (red) in pulmonary tissue. Nuclei were counterstained with HOECHST (blue). Scale bar = 50 lm. The right panel shows
the number of CXCR4+ cells per vessel (5 fields per section). Same details as in Fig. 1.
Fig. 7 Outcome of altered recruitment of
c-kit+ cells. (A) Quantification in 10 fields/
sample of the number of vessels with
diameter <50 lm. (B) Morphometric anal-
ysis performed on 20 pulmonary vessels
(<50 lm diameter) to assess the percent-
age of medial wall thickness of pulmonary
arteries. (C) Right ventricular hypertrophy,
calculated as the weight of RV/left ventri-
cle + septum. Right panel. (D) Left and
the right ventricular pressures. Same
details as in Fig. 1.
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cells are the key drivers of lung remodelling and inflammation in a
mouse model of this condition [26]. On this basis, it can be argued
that reducing mobilization/recruitment of BM cells during CH may
represent a good strategy to prevent adverse pulmonary remodelling.
Here, to further shed light on these processes and in the attempt
to find novel mechanistic insights, we employed a well-established
CH model [19] to establish the effect of sildenafil (1.4 mg/kg i.p., a
dose compatible with that used for treatment of heart failure in human
beings [14]) in PH.
As expected [4–6], CH enhanced the number of c-kit+ cells, a
specific population of BM cells, in pulmonary artery (Fig. 2) and was
associated with increased small pulmonary vessels (Fig. 7A). This is
in agreement with previous investigation showing that c-kit+ cells par-
ticipate in the new vessel formation process during chronic hypoxia
[5]. To substantiate these findings, we showed that CH markedly
increases the number of c-kit+ cells colocalizing with VEGF-R2 and
CD68 receptors. As VEGF-2R is a marker for pro-angiogenesis pro-
genitor cells [27], the accumulation of c-kit+/VEGF-R2+ cells in CH
might imply greater potential for the genesis of pulmonary arteries.
We found that CH augments the number of c-kit+/CD68+ cells (mono-
cytes/macrophages), consistently with a previous report showing
increased infiltration of inflammatory cells in pulmonary tissues of
patients with idiopathic PH [28].
This study provides the first evidence that sildenafil prevents
small pulmonary vessel remodelling in CH contrasting the recruitment
of all the cell types mentioned above that express the c-kit marker in
the hypoxic lung. Although not conclusive, the presented data sug-
gest that sildenafil reduces the potential deleterious effects of c-kit+
cells in the CH scenario. Indeed, a pathogenic role for c-kit+ cells in
CH was recently suggested by the finding that imatinib, a tyrosine
kinase inhibitor blocking c-kit receptor, improves pulmonary arterial
remodelling by decreasing the recruitment of c-kit+ cells in pulmonary
arterial lesions of hypoxic mice [6].
However, we cannot exclude that sildenafil prevents reverse
remodelling in lung during CH by acting also on other cell types and
with parallel mechanisms. In facts, we and others [29] have shown
that sildenafil attenuates at least two mechanisms that are crucial in
the process of vascular remodelling: the hypoxia-induced VSMC pro-
liferation and the hypoxia-induced inflammatory cell recruitment.
Whereas VSMC phenotypic switching contributes to the structural
changes observed in the pulmonary arteries during CH [30], emerging
evidence demonstrates that inflammatory cells accumulate at perivas-
cular sites in the hypoxic lungs [30].
Noteworthy, sildenafil also attenuates CXCR4+ mobilization and the
subsequent recruitment into the remodelled pulmonary arteries
(Fig. 6B). The chemokine receptor CXCR4 is highly expressed in
immune cells and mediates the migration of resting leucocytes and
haematopoietic progenitors in response to its ligand, SDF-1a. The lat-
ter and its receptor CXCR4 have been shown to be critical for homing
and mobilization of c-kit+ progenitor cells in response to tissue hypoxia
[31, 32]. Thus, we believe that sildenafil decreases c-kit+ cell recruit-
ment to the damaged lung mainly by acting on the SDF-1a/CXCR4
axis. To further support this paradigm, it was reported that the admin-
istration of AMD3100, a CXCR4 antagonist, attenuates hypoxia-induced
PH by reducing pulmonary c-kit+ progenitor cell accumulation [6].
Intriguingly, in this study sildenafil reduced the number of
CXCR4+ progenitor cells in the pulmonary artery adventitia but
not the CH-induced expression of HIF-1a. This indicates that
sildenafil decreases CXCR4+ cells recruitment without affecting
the degree of hypoxia, as confirmed by conserved haematocrit
and blood gas analysis (Table 1). It is thus likely that the benefi-
cial effects of sildenafil remain linked, at least in part, to the
activation of the NO/cGMP and the PI3K/Akt signalling pathways.
Remarkably, the recovery in Akt/eNOS activation by sildenafil
suggests a mechanism with relevant impact on the inflammatory
response. Indeed, it was reported that Akt is upstream eNOS
phosphorylation [33] and that eNOS-derived NO plays an impor-
tant role in inhibiting macrophage infiltration into the lungs of
PH patients [34].
In conclusion, this study provides the first evidence that
PDE-5 inhibition by sildenafil is associated with a reduction in
the mobilization and homing of c-kit+ cells to the hypoxic lung.
This association may be linked to the effect of sildenafil in the
prevention of pulmonary vascular remodelling induced by CH.
The underlying mechanism appears to involve the modulation of
the SDF-1a/CXCR4 axis as well as the Akt/eNOS pathway to con-
trast the inflammatory pulmonary drive during hypoxia. These
results highlight a novel paradigm for the clinical use of sildenafil
in the management of PH.
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